We are a discovery-driven venture spun out of the Camilli Lab at Tufts University School of Medicine in Boston. PhagePro aims to use bacteriophages, which are viruses that specifically target and kill bacteria, to prevent bacterial infections.

With the unmitigated rise of antibiotic resistance and the known negative consequences of gut dysbiosis caused by broad-spectrum antibiotics, bacteriophages provide a side effect-free alternative for preventing disease in clinical and community contexts. 


Our Mission

PhagePro is an early-stage biotechnology therapeutics company that develops bacteriophage-based products to help the world’s most vulnerable communities prosper.